Avastin will remain gold standard for lung cancer to 2018

pharmafile | June 20, 2010 | News story | |  Decision Resources, NSCLC, Roche drug tipped to remain key to treatment, avastin 

 Industry analysts Decision Resources believes that Roche’s Avastin plus chemotherapy agents will remain as the gold standard for the treatment of non-small cell lung cancer.

The analysts state that Avastin (bevacizumab) plus the chemotherapy regimens paclitaxel and carboplatin have the highest combined level of efficacy in treating advanced non-small cell lung cancer (NSCLC) and believe it will remain the best standard of care through to 2018.

Decision Resources (DR) found that clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over Avastin plus chemotherapy.

DR analyst Laila Siddique, said: “The bevacizumab/ paclitaxel/ carboplatin regimen attains current and future gold-standard status based on its superior overall survival in patients with advanced non-small-cell lung cancer.”

“Oncologists we surveyed are enthusiastic about the improvements seen in efficacy resulting from the addition of bevacizumab to chemotherapeutic agents,” added Ms Siddique.

“This enthusiasm however, stems solely from the ability of the regimen to increase overall survival beyond that seen with chemotherapy doublets.”

Avastin is currently the top selling cancer drug in the world with indications in colon, lung, kidney and brain cancer and phase III trials in ovarian cancer.

 

Related Content

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast …

Merck and Moderna initiate phase 3 study of NSCLC treatment

Merck (known as MSD outside of the US and Canada) and Moderna have announced the …

Latest content